Watson Pharmaceuticals
Also known as: Qingdao Co-orient Watson Biotechnology group co. LTD | ROYCE LABS | Watson Laboratories | Watson Laboratories, Inc. | WATSON LABS | WATSON LABS FLORIDA | WATSON LABS INC | WATSON LPHARMACEUTICAL | Watson Pharmaceuticals | Watson Pharmaceuticals, Inc. | WATSON PHARMS INC | WATSON PHARMS TEVA
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2002First marketed drug
Jul 1, 1983First NDA
Oct 8, 2008Last known activity
Feb 1, 2020
Timeline
1980s
- Jul 1, 1983
Watson Pharmaceuticals— Founded
- Apr 18, 1986
propranolol— Marketing Organization
1990s
- Jan 1, 1995
Circa Pharmaceuticals— Acquired
- Jan 1, 1996
Oclassen— Acquired
2000s
- Jun 1, 2000
Halsey— Acquired
- Aug 1, 2000
Henry Schein, Inc— Acquired
- Nov 6, 2006
Andrx— Acquired
- Oct 8, 2008
silodosin— NDA Organization
2010s
- Jan 1, 2010
Eden Biodesign— Acquired
- May 25, 2011
Specifar Pharmaceuticals S.A.— Acquired
- Jan 1, 2012
Actavis Group (1956)— Acquired
- Jan 30, 2012
Ascent Pharmahealth— Acquired
- Apr 25, 2012
Actavis— Acquired By
- Jan 24, 2013
Uteron Pharma S.A.— Acquired
- Feb 12, 2016
rosuvastatin— NDA Secondary Org
- Jun 26, 2019
AbbVie— Now
Drugs by trial phase (132 distinct, 333 trials)
Phase 4 (8 own, 6 via acquisition)
Phase 3 (10 own, 19 via acquisition)
Phase 2 (3 own, 40 via acquisition)
Phase 1 (1 own, 44 via acquisition)
Other trials (0 own, 1 via acquisition)
Indications
Approved for
Studied for
- Acne Vulgaris
- Anemia
- Anemia, Iron-Deficiency
- Calculi
- Chronic Disease
- Cystitis
- Cystitis, Interstitial
- Deficiency Diseases
- Erythema
- Hemorrhage
- Hyperhidrosis
- Hyperplasia
- Hypogonadism
- Inflammation
- Kidney Calculi
- Kidney Diseases
- Kidney Failure, Chronic
- Leiomyoma
- Lupus Erythematosus, Systemic
- Malnutrition
- Myofibroma
- Nephrolithiasis
- Nocturia
- Pain
- Pelvic Pain
- Pneumonia
- Polycystic Ovary Syndrome
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Prostatitis
- Reflex, Abnormal
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Rosacea
- Signs and Symptoms
- Somatoform Disorders
- Syndrome
- Ureteral Calculi
- Ureterolithiasis
- Urinary Bladder, Neurogenic
- Urinary Bladder, Overactive
- Urinary Calculi
- Urinary Incontinence
- Urolithiasis
- Uterine Hemorrhage
- Vaginal Discharge
- Vaginal Diseases
- Vaginosis, Bacterial
Marketed drugs (350)
Subsidiaries (10 direct, 60 total across the full acquisition tree)
- Actavis Group (1956)
- Andrx
- Ascent Pharmahealth
- Circa Pharmaceuticals
- Eden Biodesign
- Halsey
- Henry Schein, Inc
- Oclassen
- Specifar Pharmaceuticals S.A.
- Uteron Pharma S.A.
- Accord Dental L2
- Alpha Scientific L2
- Arcona L2
- Armstrong Pharmaceuticals L2
- Ash Temple L2
- Barton-Cyker Dental Supply L2
- Butler Animal Health L2
- Caligor Hospital L2
- Colonial Surgical L2
- CTEX Pharmaceuticals L2
- Dentrix Dental Systems L2
- GIV L2
- Hager Dental L2
- Halas Dental L2
- Heiland L2
- ImproMed L2
- Krugg L2
- Lincoln Dental Supply L2
- Maravet L2
- Marsam Pharmaceuticals L2
- McAllister Software Systems L2
- Medivet S.A. L2
- Medka L2
- Meer Dental L2
- Minerva Dental, Ltd L2
- Modern Laboratory Services L2
- NLS Animal Health L2
- Noviko L2
- Ortho Oganizers L2
- Ortho Technology L2
- Permira L2
- Provet Holding AG L2
- Regional Healthcare (Australia) L2
- RxWorks L2
- Scil Technology GmbH L2
- Shalfoon Brothers L2
- Software of Excellence International, Ltd. L2
- Sogim Grimouille L2
- Sullivan Dental Products L2
- Vertex L2
- W&J Dunlop Ltd L2
- Zahn Dental L2
- Alpine Immune Sciences L3
- Aurora Biosciences L3
- Exonics L3
- Muller & Weygandt L3
- Semma Therapeutics L3
- ViaCyte L3
- ViroChem Pharma L3
- Nivalis Therapeutics, Inc. L4
Recent trials (50)
- NCT04339660CollaboratorPhase 1/Phase 2Feb 1, 2020
- NCT02289352CollaboratorPhase 3Jul 1, 2014
- NCT02147197Lead sponsorPhase 3Apr 1, 2014
- NCT02210689CollaboratorPhase 3Jan 1, 2014
- NCT02147158Lead sponsorPhase 3Jan 1, 2014
- NCT02193139Lead sponsorPhase 2Dec 1, 2013
- NCT01850823CollaboratorPhase 3Feb 1, 2013
- NCT03440359CollaboratorPhase 2/Phase 3Jul 6, 2012
- NCT01788384Lead sponsorPhase 3Jul 1, 2012
- NCT01553123Study directorPhase 3Apr 1, 2012
- NCT01553123Lead sponsorPhase 3Apr 1, 2012
- NCT01192568Lead sponsorPhase 4May 1, 2011
- NCT01323140Lead sponsorPhase 2Apr 1, 2011
- NCT01323140Study directorPhase 2Apr 1, 2011
- NCT01161563Study directorPhase 4Jul 1, 2010
Details
- Founded
- Corona, CA, US Jul 1, 1983
- First NDA
- Oct 8, 2008
- Last known activity
- Feb 1, 2020
Notes
Acquired by Actavis 24 Jan 2013 Acquired Uteron Pharma Acquired Eden Biopharma Acquired Andrx Corp.